Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Interventional × lortalamine × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Disease 1

Interventions

Cisplatin 723 Carboplatin 605 Paclitaxel 575 Cyclophosphamide 517 Radiotherapy 510 Docetaxel 473 Fluorouracil 449 Gemcitabine 432 Doxorubicin 384 Capecitabine 357 Dexamethasone 324 Oxaliplatin 284 Leucovorin 281 pembrolizumab 279 Vincristine 271 Etoposide 271 Bevacizumab 271 Rituximab 245 Prednisone 223 Pemetrexed 217 Cytarabine 204 Drug Therapy 193 Trastuzumab 174 Methotrexate 171 Irinotecan 169 Lenalidomide 136 Filgrastim 135 Nivolumab 134 Epirubicin 129 Tamoxifen 127

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡